Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 1/20 | 0.39 |
| ▸ | SCN4A | P35499 | 1/20 | 0.39 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.39 |
| ▸ | SCN11A | Q9UI33 | 1/20 | 0.39 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4012058 | 1.00 | SCN1A (0.39) | SCN1ASCN4ASCN7AKCNH2SCN5A | |
| SCHEMBL8529811 | 0.97 | SCN1A (0.41) | SCN1ASCN4ASCN7AKCNH2SCN5A | |
| SCHEMBL1630078 | 0.97 | SCN1A (0.41) | SCN1ASCN4ASCN7AKCNH2SCN5A | |
| SCHEMBL2993610 | 0.97 | SCN1A (0.41) | SCN1ASCN4ASCN7AKCNH2SCN5A | |
| SCHEMBL4655278 | 0.97 | SCN1A (0.41) | SCN1ASCN4ASCN7AKCNH2SCN5A | |
| SCHEMBL181178 | 0.97 | SCN1A (0.41) | SCN1ASCN4ASCN7AKCNH2SCN5A | |
| SCHEMBL4697737 | 0.97 | SCN1A (0.41) | SCN1ASCN4ASCN7AKCNH2SCN5A | |
| SCHEMBL30492082 | 0.97 | SCN1A (0.41) | SCN1ASCN4ASCN7AKCNH2SCN5A | |
| SCHEMBL6079568 | 0.94 | SCN1A (0.39) | SCN1ASCN4ASCN7AKCNH2SCN5A | |
| SCHEMBL1814570 | 0.94 | SCN1A (0.42) | SCN1ASCN4ASCN7AKCNH2SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2668179-B1 | NEW 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INT (DE) | 2017-08-16 | — | — | EP | claimed |
| EP-2668178-B1 | NEW 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INT (DE) | 2016-01-20 | — | — | EP | claimed |
| WO-2023218484-A1 | BICYCLIC COMPOUNDS AND THEIR USE AS PEST CONTROL AGENTS | PI INDUSTRIES LTD. (IN) | 2023-11-16 | — | — | WO | disclosed |
| EP-1829874-B1 | TRICYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2014-02-12 | — | — | EP | disclosed |
| EP-2399905-A1 | SULFONIUM SALT, PHOTO-ACID GENERATOR, AND PHOTOSENSITIVE RESIN COMPOSITION | San-Apro Limited (JP) | 2011-12-28 | — | — | EP | disclosed |
| WO-2008135488-A1 | ASPARTYL PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2008-11-13 | — | — | WO | disclosed |
| WO-2007017179-A1 | USE OF IONIC UV-A SUNSCREENS | DSM IP ASSETS B.V. (NL) | 2007-02-15 | — | — | WO | disclosed |
| EP-1599465-A1 | SUBSTITUTED N-ARYL NITROGEN HETEROCYCLES | Bayer CropScience AG (DE) | 2005-11-30 | — | — | EP | disclosed |
| US-20040242876-A1 | Process for the preparation of (pyrimmidin-2-yl) methyl ketones | LONZA LTD. (CH) | 2004-12-02 | — | — | US | disclosed |
| WO-2004074274-A1 | SUBSTITUTED N-ARYL NITROGEN HETEROCYCLES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2004-09-02 | — | — | WO | disclosed |
| US-6780992-B2 | 5-(4-(2-(2,4-DIMETHYL-6-OXO-1,6-DIHYDRO-1-PYRIMIDINYL) -ETHOXY)PHENYL METHYL)THIAZOLIDINE-2,4-DIONE FOR EXAMPLE; ALSO OXAZOLIDINE-2,4-DIONE, AND 1,2,4-OXADIAZOLIDINE-3,5-DIONE DERIVATIVES; REDUCING BLOOD GLUCOSE LEVELS | DR. REDDY'S LABORATORIES LTD. (IN) | 2004-08-24 | — | — | US | disclosed |
| US-20020123502-A1 | Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases | DR. REDDY'S RESEARCH FOUNDATION & REDDY-CHEMINOR, INC. | 2002-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020123502-A1 | Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases | IAPP, GPR119, CYP11B1 | SCN1A 1764/4885SCN4A 1155/4885SCN7A 1903/4885 |
| US-20040242876-A1 | Process for the preparation of (pyrimmidin-2-yl) methyl ketones | MRM1, CYP2E1, CBR1 | SCN1A 3145/4885SCN4A 3679/4885SCN7A 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.